Biotech Bearish Stocks: Reliv International (NASDAQ:RELV), Ocera Therapeutics (NASDAQ:OCRX), MediciNova (NASDAQ:MNOV), PTC Therapeutics (NASDAQ:PTCT)

Registrant and three of its wholly-owned subsidiaries, Reliv, International, Inc (NASDAQ:RELV), Reliv World Corporation and SL Technology, Inc. entered into a Credit Agreement with BMO Harris Bank N.A. (the “Bank”) pursuant to which the Bank agreed to provide certain credit facilities to Registrant, including a Term Loan in the principal amount of $3,481,961 and a revolving credit facility in the amount of $5,000,000. Reliv International, … Continue reading Biotech Bearish Stocks: Reliv International (NASDAQ:RELV), Ocera Therapeutics (NASDAQ:OCRX), MediciNova (NASDAQ:MNOV), PTC Therapeutics (NASDAQ:PTCT)

Jayne Crisman04/0304/03

Healthcare Decliners: Escalon Medical (NASDAQ:ESMC), CorMedix Inc. (NYSEMKT:CRMD), Ocera Therapeutics Inc (NASDAQ:OCRX), Marina Biotech (OTCMKTS:MRNA)

Escalon Medical Corp. (NASDAQ:ESMC) trades at a significant discount to its peer group as the lack of investor (and analyst) following results in the successful “shrink to grow” strategy being ignored. The company is now a pure play with no debt, cash that represents ~20% of the market cap, overlooked tax assets and a significantly lower cash burn rate. Escalon Medical Corp. (NASDAQ:ESMC) stock performance … Continue reading Healthcare Decliners: Escalon Medical (NASDAQ:ESMC), CorMedix Inc. (NYSEMKT:CRMD), Ocera Therapeutics Inc (NASDAQ:OCRX), Marina Biotech (OTCMKTS:MRNA)

Richard Atkins04/0104/01

Biotech Decliners: Ocera Therapeutics Inc (NASDAQ:OCRX), Marina Biotech, Inc. (OTCMKTS:MRNA), CorMedix Inc. (NYSEMKT:CRMD), Idera Pharmaceuticals Inc (NASDAQ:IDRA)

Ocera Therapeutics Inc (NASDAQ:OCRX) is a company with one main value driver, OCR002. Financially, the company is now sitting on $47.2 M and will be spending $30M in the 2014 financial year. It has about one year in cash. Last year, it spent $3.5M in R&D and these costs are set to increase as it ramps up the Phase 2 trials for OCR002. Ocera Therapeutics … Continue reading Biotech Decliners: Ocera Therapeutics Inc (NASDAQ:OCRX), Marina Biotech, Inc. (OTCMKTS:MRNA), CorMedix Inc. (NYSEMKT:CRMD), Idera Pharmaceuticals Inc (NASDAQ:IDRA)

John Meady04/0104/01

Biotech Losers: Aegerion Pharmaceuticals (NASDAQ:AEGR), Ocera Therapeutics (NASDAQ:OCRX), Onconova Therapeutics (NASDAQ:ONTX), CYANOTECH (NASDAQ:CYAN)

Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) was a big mover last session, as its shares rose nearly 11% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the trend for the healthcare company since Feb 24, as the stock is now down nearly 19%.stock performance was -7.00% in last session and finished the … Continue reading Biotech Losers: Aegerion Pharmaceuticals (NASDAQ:AEGR), Ocera Therapeutics (NASDAQ:OCRX), Onconova Therapeutics (NASDAQ:ONTX), CYANOTECH (NASDAQ:CYAN)

Colin Pettis03/1203/12

Eye Catching Stocks: Ocera Therapeutics, Inc. (NASDAQ:OCRX), Groupon, Inc. (NASDAQ:GRPN), Renewable Energy Group, Inc. (NASDAQ:REGI), Natural Alternatives International (NASDAQ:NAII), TD Ameritrade (NYSE:AMTD)

On Nov. 13, Ocera Therapeutics, Inc. (NASDAQ:OCRX) announced recent business highlights and reported financial results for the quarter ended September 30, 2014. As of September 30, 2014, Ocera had cash, cash equivalents and investments of $55.6 million. Net loss for the three and nine months ended September 30, 2014 was $6.6 million and $17.9 million, respectively. Ocera Therapeutics, Inc. (NASDAQ:OCRX) belongs to Healthcare sector. Its … Continue reading Eye Catching Stocks: Ocera Therapeutics, Inc. (NASDAQ:OCRX), Groupon, Inc. (NASDAQ:GRPN), Renewable Energy Group, Inc. (NASDAQ:REGI), Natural Alternatives International (NASDAQ:NAII), TD Ameritrade (NYSE:AMTD)

Jayne Crisman11/28

Losers to Watch: Esperion Therapeutics Inc (NASDAQ:ESPR), Egalet Corp (NASDAQ:EGLT), Ocera Therapeutics (NASDAQ:OCRX), La Jolla Pharmaceutical (NASDAQ:LJPC), Omeros (NASDAQ:OMER)

In June, Esperion Therapeutics Inc. (NASDAQ:ESPR), an Ann Arbor-based early-stage pharmaceutical company, raised $73 million in its IPO. It plans a secondary offering this year, based on trial results of its cholesterol-lowering drug. Esperion Therapeutics Inc (NASDAQ:ESPR) stock performance was -5.04% in last session and finished the day at $14.69. Traded volume was 31,400 shares in the last session and the average volume of the … Continue reading Losers to Watch: Esperion Therapeutics Inc (NASDAQ:ESPR), Egalet Corp (NASDAQ:EGLT), Ocera Therapeutics (NASDAQ:OCRX), La Jolla Pharmaceutical (NASDAQ:LJPC), Omeros (NASDAQ:OMER)

John Bellich08/1408/14